SAN DIEGO, CA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, announced today that Jim DeMesa, MD, Chief Executive Officer of Emerald Health Pharmaceuticals will present at Rodman & Renshaw’s 21st Annual Global Investment Conference on September 10th in New York City and the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit (iCDP) on September 12th in Boston.
Rodman & Renshaw’s 21st Annual Global Investment Conference
Dr. DeMesa will present a corporate overview at Rodman & Renshaw’s 21st Annual Global Investment Conference to be held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York, NY, with follow-up investor meetings held throughout the conference. Details of the presentation are as follows:
Date & Time: Tuesday, September 10, 2019 at 3:50 PM EDT
Location: Lotte New York Palace Hotel, NY; Kennedy I Room (4th Floor)
To view the live webcast, please access the following link at the time of the presentation: http://wsw.com/webcast/hcw5/ehpi/. An archived version of the webcast will be available for 90 days in the investor section of the Emerald Health Pharmaceuticals website.
For more information about this conference, please visit: http://www.rodmanevents.com.
2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit (iCDP)
Dr. DeMesa will be a featured speaker at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit (iCDP) to be held on September 10-12, 2019 at the Aloft Boston Seaport in Boston, MA. Details of the presentation are as follows:
| Session: | Challenges in Clinical Trials & Linking Cannabinoids to their Areas of Therapeutic Potential |
| Presentation: | From Marijuana to New Chemical Entity: The Path to the Clinic |
| Date & Time: | Thursday, September 12, 2019 at 12:00 PM EDT |
| Location: | Aloft Boston Seaport, 401-403 D St., Boston, MA, 02210, USA |
For more information about this conference, please visit: www.international-cdp.com.
About Emerald Health Pharmaceuticals Inc.
Emerald Health Pharmaceuticals is developing product candidates for the treatment of central nervous system (CNS), autoimmune, and other diseases. The Company has two families of new chemical entities, derived from synthetic cannabidiol (CBD) and cannabigerol (CBG), that it has modified through rational drug design to affect validated receptors and pathways pertinent to targeted diseases. Its first drug candidate, EHP-101, has completed a Phase I clinical study and is being developed for the treatment of multiple sclerosis and systemic scleroderma. Phase II studies are planned to begin by the end of 2019. Its second drug candidate, EHP-102, is in preclinical development and is focused on treating Huntington’s disease and Parkinson’s disease. For more information, visit http://www.emeraldpharma.life or contact: info@emeraldpharma.life.
To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered "forward-looking statements," as described in the private securities litigation reform act of 1995, that reflect management's current beliefs and expectations. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "hope," "hypothesis," "intend," "may," "plan," "potential," "predict," "project," "should," "strategy," "will," "would," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this news release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; (v) our ability to meet our milestones; and (vi) our expectations regarding our ability to obtain and maintain intellectual property protection. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.